456 related articles for article (PubMed ID: 30963202)
1. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
Hong H; Budhathoki C; Farley JE
Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
[TBL] [Abstract][Full Text] [Related]
3. Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Int J Tuberc Lung Dis; 2020 Jan; 24(1):65-72. PubMed ID: 32005308
[No Abstract] [Full Text] [Related]
4. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
[TBL] [Abstract][Full Text] [Related]
5. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
[TBL] [Abstract][Full Text] [Related]
6. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients.
Harris T; Bardien S; Schaaf HS; Petersen L; De Jong G; Fagan JJ
S Afr Med J; 2012 May; 102(6 Pt 2):363-6. PubMed ID: 22668907
[TBL] [Abstract][Full Text] [Related]
7. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
8. Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides.
Human H; Hagen CM; de Jong G; Harris T; Lombard D; Christiansen M; Bardien S
Biochem Biophys Res Commun; 2010 Mar; 393(4):751-6. PubMed ID: 20171168
[TBL] [Abstract][Full Text] [Related]
9. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Clin Infect Dis; 2020 Feb; 70(5):917-924. PubMed ID: 30963176
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
[TBL] [Abstract][Full Text] [Related]
11. The lived experiences and psychosocial impact of hearing loss on the quality of life of adults with Multidrug-Resistant Tuberculosis.
Thusi AB; Paken J
S Afr J Commun Disord; 2022 Feb; 69(1):e1-e13. PubMed ID: 35261255
[TBL] [Abstract][Full Text] [Related]
12. ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death.
Ogier JM; Gao Y; Dunne EM; Wilson MA; Ranganathan SC; Tesch GH; Nikolic Paterson DJ; Dabdoub A; Burt RA; Nayagam BA; Lockhart PJ
J Mol Med (Berl); 2022 May; 100(5):797-813. PubMed ID: 35471608
[TBL] [Abstract][Full Text] [Related]
13. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
[TBL] [Abstract][Full Text] [Related]
14. Berberine chloride protects cochlear hair cells from aminoglycoside-induced ototoxicity by reducing the accumulation of mitochondrial reactive oxygen species.
Kim YR; Baek JI; Lee KY; Kim UK
Free Radic Biol Med; 2023 Aug; 204():177-183. PubMed ID: 37119862
[TBL] [Abstract][Full Text] [Related]
15. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal community-based ototoxicity monitoring programme and treatment effects for drug-resistant tuberculosis treatment, Western Cape.
Stevenson LJ; Biagio-de Jager L; Graham MA; Swanepoel W
S Afr J Commun Disord; 2022 Mar; 69(1):e1-e13. PubMed ID: 35384675
[TBL] [Abstract][Full Text] [Related]
18. Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon.
Mpoh MM; Deli V; Daniel TT; Salvo F
Int J Mycobacteriol; 2023; 12(2):168-174. PubMed ID: 37338479
[TBL] [Abstract][Full Text] [Related]
19. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis.
Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
Rev Soc Bras Med Trop; 2017; 50(5):646-651. PubMed ID: 29160511
[TBL] [Abstract][Full Text] [Related]
20. Synergistic ototoxicity due to noise exposure and aminoglycoside antibiotics.
Li H; Steyger PS
Noise Health; 2009; 11(42):26-32. PubMed ID: 19265251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
